Open in interactive viewer → charts, metric popovers & call review

Cardiff Lexington: A $2.5 Million Interest Bill Against $1.9 Million of Revenue

The Q3 call wasn't an earnings report — it was a solvency briefing, and management told shareholders to their face that the cure is dilution.
CDIX · Earnings Call · 2026-11-16

Cardiff Lexington is a healthcare company with a $271 thousand market capitalization that reported a $3.2 million quarterly net loss on Monday. Set those two numbers side by side and you have the whole dossier: the equity is a stub, and the loss is more than ten times the value of the equity that produced it.

What management chose to do with the call was unusual. Rather than dress a bad quarter in operating-improvement language, CEO Alex Cunningham spent the first five minutes of prepared remarks on a proposed merger and then conceded, in the only Q&A question of the session, that the deal would cost existing holders most of their ownership. That is not a growth story. That is a recapitalization with a healthcare business attached.

“The short answer is yes”

Analyst Andrea Grieco asked whether Cardiff's existing shareholders “could end up owning a much smaller percentage of the company while new investors and sellers receive preferential treatment” — Andrea Grieco, Analyst · 2026-11-16. The answer was immediate and, to the CEO's credit, unhedged:

The short answer is yes, because the proposed transaction involves bringing in new equity, refinancing and giving sellers significant equity in the company. Our existing shareholders will see their ownership percentage diluted, and those new investors will receive preferential rights.

Alex Cunningham, Chief Executive Officer · 2026-11-16

The proposed acquisition — a letter of intent signed in September for a multi-location musculoskeletal platform — is explicitly framed as a balance-sheet transplant. The target is described as carrying “little to no appreciable debt and a very strong balance sheet” — Alex Cunningham, Chief Executive Officer · 2026-11-16, and its healthy balance sheet is precisely the asset Cardiff does not have. The structure bundles debt restructuring, significant new equity from new investors, and seller rollover — a “long-term combination rather than simply an acquisition,” in the CEO's phrasing.

Look at what the company's own keyword set says about the quarter. The top of the list is almost pure securities-law vocabulary: ownership percentage, definitive agreement, combined organization, and the safe-harbor tail of “changed conditions” and “guarantees of future.” There is not a single clinical, procedure-volume, or payer-mix theme anywhere in the top thirty. The only keyword in Cardiff's entire momentum history that ever spiked upward is Cardiff — the company's own name. When your name is your best keyword, you don't have a thematic story; you have a corporate event.

The interest expense is the verdict on the business model

Third-quarter revenue was $1.9 million against $3.1 million a year earlier. Gross profit fell to $1.0 million, or 54.2% of sales, from 62.4%. The long arc isn't kind either: revenue peaked at $3 million in Q3 2022 and remains roughly a fifth below that high, and gross margin has slipped about six points year over year.

But the gross margin is fine. The problem is one line item. Interest expense in the quarter was $2.5 million — larger than the company's entire revenue, larger than gross profit, and 39% higher than the $1.8 million in the prior-year period. CFO Matt Shafer attributed it to “higher initial and incremental fees charged on existing purchases and claims under our line of credit, which, as Alex alluded to and as we've discussed on prior calls, reflects the higher-cost financing structures that we've used to fund our business” — Matthew Shafer, Chief Financial Officer · 2026-11-16. That parenthetical matters: the higher cost financing structures and high finance charges are not a one-quarter anomaly. They are a recurring, structural feature of how this company funds itself, disclosed on call after call.

The result: a $537 thousand loss from continuing operations, a $3.2 million net loss, and a negative adjusted EBITDA of $279 thousand versus positive $663 thousand a year ago. Total revenue for the first nine months fell to $6.3 million from $8.8 million, and year-to-date adjusted EBITDA swung to a $292 thousand loss from $1.9 million of profit.

Share-based compensation of $370 thousand against $41 thousand a year earlier is doing quiet work in that bridge — roughly a fifth of a single quarter's revenue was paid in stock rather than dollars. Meanwhile the operating line has been negative in most recent quarters, including a $545 thousand operating loss in the latest filed period.

A receivable book wearing a clinic

Here is the insight buried under the merger talk. Cardiff's Nova Ortho and Spine network — 11 locations across Florida and Georgia — is not really an operating business being strangled by working capital. It is a claims-settlement receivable book financed at punishing rates, with clinics attached.

Look at the balance sheet the CFO walked through: $584 thousand of cash, $23.4 million of net accounts receivable, total liabilities of $29 million against total assets of $30.6 million. Against $6.3 million of nine-month revenue, that receivable book is nearly four turns of annual revenue. Effective net cash sat at negative $843 thousand, having careened from deeply negative through 2025 to roughly flat today — the fingerprint of continuous refinancing, not of an operating turnaround.

And the receivable book is getting worse, not better. The implicit realization rate on patient case settlement claims fell to 40% from 42%, and procedure counts fell — “a lower realization rate on patient case claim settlements as well as a decrease in procedures” — Matthew Shafer, Chief Financial Officer · 2026-11-16. You are collecting less per claim and treating fewer patients, while paying more to finance the wait. Cunningham was blunt about the cause: “working capital constraints have limited our ability to capitalize on opportunities” — Alex Cunningham, Chief Executive Officer · 2026-11-16 — and, later, “Something has to change, and we believe the best thing that we can do is to drive performance of the business and seek to remedy the undercapitalization driving perpetual working capital constraints” — Alex Cunningham, Chief Executive Officer · 2026-11-16.

That is management admitting that the constraint is chronic, not temporal. Which is why the operative word in the whole transcript is long term viability — not growth, not margin, not returns on capital. Viability.

No crowd to lean on

There is no confluence here. The market's own last-quarter keyword board was consumed by rates, tariffs and AI infrastructure, and the healthcare-services names that are actually moving — ACHC, RDNT, SGRY, UNH, HUM — do so on themes like number of centers, gap in care and Site of service, all of which advanced on the 30- and 90-day tapes. Cardiff gestures at that language — an underserved population, eleven locations — but never engages its economics: no payer mix, no Medicare Advantage membership, no unit buildout math.

Nor is there a tape to read: the price series is null, and at a $271 thousand market cap there is barely a float worth pricing. There is also no press coverage in the window. A reader looking for external corroboration will find none — which is itself informative.

The next checkpoint is December. Management “currently anticipate further progress in December, although no definitive execution date has been established” — Alex Cunningham, Chief Executive Officer · 2026-11-16, and the letter of intent is nonbinding. That gives holders a binary: a definitive agreement that brings new capital but hands control and preferential rights to new money, or a standalone path where “there are no guarantees those standalone efforts will be enough in the long term” — Alex Cunningham, Chief Executive Officer · 2026-11-16. The CEO closed by saying he'd talk to investors again in March. Whether there is a company worth talking about depends entirely on the next thirty days of paperwork.